Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The Role of Properdin in Zymosan- and Escherichia coli-Induced Complement Activation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Harboe, M, Garred, P, Lindstad, JK, Pharo, A, Müller, F, Stahl, GL, Lambris, JD & Mollnes, TE 2012, 'The Role of Properdin in Zymosan- and Escherichia coli-Induced Complement Activation' Journal of Immunology, bind 189, nr. 5, s. 2606-13. https://doi.org/10.4049/jimmunol.1200269

APA

Harboe, M., Garred, P., Lindstad, J. K., Pharo, A., Müller, F., Stahl, G. L., ... Mollnes, T. E. (2012). The Role of Properdin in Zymosan- and Escherichia coli-Induced Complement Activation. Journal of Immunology, 189(5), 2606-13. https://doi.org/10.4049/jimmunol.1200269

CBE

MLA

Vancouver

Author

Harboe, Morten ; Garred, Peter ; Lindstad, Julie K ; Pharo, Anne ; Müller, Fredrik ; Stahl, Gregory L ; Lambris, John D ; Mollnes, Tom Erik. / The Role of Properdin in Zymosan- and Escherichia coli-Induced Complement Activation. I: Journal of Immunology. 2012 ; Bind 189, Nr. 5. s. 2606-13.

Bibtex

@article{9b66a445b6b44fbabb247843bb3d71a7,
title = "The Role of Properdin in Zymosan- and Escherichia coli-Induced Complement Activation",
abstract = "Properdin is well known as an enhancer of the alternative complement amplification loop when C3 is activated, whereas its role as a recognition molecule of exogenous pathogen-associated molecular patterns and initiator of complement activation is less understood. We therefore studied the role of properdin in activation of complement in normal human serum by zymosan and various Escherichia coli strains. In ELISA, microtiter plates coated with zymosan induced efficient complement activation with deposition of C4b and terminal complement complex on the solid phase. Virtually no deposition of C4b or terminal complement complex was observed with mannose-binding lectin (MBL)-deficient serum. Reconstitution with purified MBL showed distinct activation in both readouts. In ELISA, normal human serum-induced deposition of properdin by zymosan was abolished by the C3-inhibiting peptide compstatin. Flow cytometry was used to further explore whether properdin acts as an initial recognition molecule reacting directly with zymosan and three E. coli strains. Experiments reported by other authors were made with EGTA Mg(2+) buffer, permitting autoactivation of C3. We found inhibition by compstatin on these substrates, indicating that properdin deposition depended on initial C3b deposition followed by properdin in a second step. Properdin released from human polymorphonuclear cells stimulated with PMA did not bind to zymosan or E. coli, but when incubated in properdin-depleted serum this form of properdin bound efficiently to both substrates in a strictly C3-dependent manner, as the binding was abolished by compstatin. Collectively, these data indicate that properdin in serum as well as polymorphonuclear-released properdin is unable to bind and initiate direct alternative pathway activation on these substrates.",
author = "Morten Harboe and Peter Garred and Lindstad, {Julie K} and Anne Pharo and Fredrik M{\"u}ller and Stahl, {Gregory L} and Lambris, {John D} and Mollnes, {Tom Erik}",
year = "2012",
doi = "10.4049/jimmunol.1200269",
language = "English",
volume = "189",
pages = "2606--13",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

RIS

TY - JOUR

T1 - The Role of Properdin in Zymosan- and Escherichia coli-Induced Complement Activation

AU - Harboe, Morten

AU - Garred, Peter

AU - Lindstad, Julie K

AU - Pharo, Anne

AU - Müller, Fredrik

AU - Stahl, Gregory L

AU - Lambris, John D

AU - Mollnes, Tom Erik

PY - 2012

Y1 - 2012

N2 - Properdin is well known as an enhancer of the alternative complement amplification loop when C3 is activated, whereas its role as a recognition molecule of exogenous pathogen-associated molecular patterns and initiator of complement activation is less understood. We therefore studied the role of properdin in activation of complement in normal human serum by zymosan and various Escherichia coli strains. In ELISA, microtiter plates coated with zymosan induced efficient complement activation with deposition of C4b and terminal complement complex on the solid phase. Virtually no deposition of C4b or terminal complement complex was observed with mannose-binding lectin (MBL)-deficient serum. Reconstitution with purified MBL showed distinct activation in both readouts. In ELISA, normal human serum-induced deposition of properdin by zymosan was abolished by the C3-inhibiting peptide compstatin. Flow cytometry was used to further explore whether properdin acts as an initial recognition molecule reacting directly with zymosan and three E. coli strains. Experiments reported by other authors were made with EGTA Mg(2+) buffer, permitting autoactivation of C3. We found inhibition by compstatin on these substrates, indicating that properdin deposition depended on initial C3b deposition followed by properdin in a second step. Properdin released from human polymorphonuclear cells stimulated with PMA did not bind to zymosan or E. coli, but when incubated in properdin-depleted serum this form of properdin bound efficiently to both substrates in a strictly C3-dependent manner, as the binding was abolished by compstatin. Collectively, these data indicate that properdin in serum as well as polymorphonuclear-released properdin is unable to bind and initiate direct alternative pathway activation on these substrates.

AB - Properdin is well known as an enhancer of the alternative complement amplification loop when C3 is activated, whereas its role as a recognition molecule of exogenous pathogen-associated molecular patterns and initiator of complement activation is less understood. We therefore studied the role of properdin in activation of complement in normal human serum by zymosan and various Escherichia coli strains. In ELISA, microtiter plates coated with zymosan induced efficient complement activation with deposition of C4b and terminal complement complex on the solid phase. Virtually no deposition of C4b or terminal complement complex was observed with mannose-binding lectin (MBL)-deficient serum. Reconstitution with purified MBL showed distinct activation in both readouts. In ELISA, normal human serum-induced deposition of properdin by zymosan was abolished by the C3-inhibiting peptide compstatin. Flow cytometry was used to further explore whether properdin acts as an initial recognition molecule reacting directly with zymosan and three E. coli strains. Experiments reported by other authors were made with EGTA Mg(2+) buffer, permitting autoactivation of C3. We found inhibition by compstatin on these substrates, indicating that properdin deposition depended on initial C3b deposition followed by properdin in a second step. Properdin released from human polymorphonuclear cells stimulated with PMA did not bind to zymosan or E. coli, but when incubated in properdin-depleted serum this form of properdin bound efficiently to both substrates in a strictly C3-dependent manner, as the binding was abolished by compstatin. Collectively, these data indicate that properdin in serum as well as polymorphonuclear-released properdin is unable to bind and initiate direct alternative pathway activation on these substrates.

U2 - 10.4049/jimmunol.1200269

DO - 10.4049/jimmunol.1200269

M3 - Journal article

VL - 189

SP - 2606

EP - 2613

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -

ID: 36331314